Chronic infection by hepatitis C virus (HCV) is a major risk factor for the onset and development of hepatocellular carcinoma (HCC), although the underlying mechanisms are unclear. The c-Myc oncogene contributes to the genesis of many types of cancers, including HCC, partly via the induction of genetic damage and the inhibition of the cellular response to genotoxic stress. Here, we show a previously undiscovered mechanistic link between HCV infection and enhanced c-Myc expression. c-Myc expression was augmented in non-tumoral liver tissues from HCV-infected individuals with or without HCC and in hepatocyte cell lines harboring an HCV replicon and the infectious HCV strain JFH1. Increased c-Myc expression was confirmed in vivo in a transgenic murine model expressing the entire HCV open reading frame, demonstrating a direct role for HCV protein expression in c-Myc induction. Mechanistically, activation of Akt by the HCV non-structural protein NS5A, and the subsequent stabilization of the transcription factor b-catenin, was demonstrated to be responsible for activation of the c-Myc promoter, and for increased c-Myc transcription. b-Catenin-dependent c-Myc expression in this context led to increased production of reactive oxygen species, mitochondrial perturbation, enhanced DNA damage and aberrant cell-cycle arrest. Together, these data provide a novel insight into the mechanisms involved in HCV-associated HCCs, strongly suggesting that c-Myc has a crucial contributory role in this process.
INTRODUCTION
Worldwide, hepatocellular carcinoma (HCC) is the most frequent malignant tumor of the liver and the third cause of cancer-related death, responsible for 6 00 000 deaths per year. 1 Cirrhosis appears to be an important, but non-specific, determinant of HCC occurrence and/or growth. 2 Chronic infection by the hepatotropic hepatitis C virus (HCV) is a major risk factor for the onset and progression of HCC, [3] [4] [5] and has become the principal cause of HCC in most industrialized areas. In HCV-infected patients, HCC most often occurs in cirrhotic subjects. However, little is known about the direct role of viral protein expression in hepatocytes in triggering and/or promoting the growth of HCCs in these patients.
Several studies using hepatoma cell lines have suggested that HCV protein expression has a direct role in tumorigenesis (reviewed in McGivern and Lemon 6, 7 ). However, the requirement for hepatoma-derived cell lines in the cultivation and study of HCV in vitro represents a major barrier to the study of HCV-associated liver tumorigenesis. Moreover, newly developed murine models of in vivo infection are currently unsuited to the study of HCV-related pathologies, since the development of pathologies such as cirrhosis or HCC have yet to be reported after long-term HCV infection in humanized mice (reviewed in Meuleman and LerouxRoels 8 and Lerat et al. 9 ). Transgenic mice of the FL-N/35 lineage, which express the entire ORF of a genotype 1b isolate of HCV, spontaneously develop HCC in the absence of cirrhosis. 10 In this model, the entire complement of viral proteins is expressed at low levels, resembling the livers of infected patients (as shown by NS3 protein expression). 11 Such expression fails to elicit an immune response, permitting the role of HCV proteins in carcinogenesis to be studied independently of the chronic inflammation usually observed during HCV infection. These animals exhibit defective apoptotic clearance of viral infection and decreased expression of the pro-apoptotic and DNA damage protein bid. 12, 13 Moreover, expression of the Gadd45b tumor suppressor is decreased in these mice, as in HCV-infected patients, due to hypermethylation of the Gadd45b promoter.
14 These mice therefore constitute an excellent model to study the role of HCV protein expression in hepatocarcinogenesis.
Oxidative stress and elevated reactive oxygen species (ROS) production are frequently observed during chronic HCV infection. They are thought to have a central role in HCV-associated HCC. [15] [16] [17] [18] Among other factors, expression of the proto-oncogene c-Myc can induce ROS production, although the mechanisms remain unclear. [19] [20] [21] [22] [23] [24] [25] Deregulated c-Myc expression, leading to its constitutive activation, has been implicated in the development of a wide range of cancers, including HCC. [26] [27] [28] [29] [30] However, the role of c-Myc in HCV-related HCC has not been unraveled thus far.
c-Myc encodes a DNA-binding nuclear transcription factor that targets a wide range of genes, including those involved in proliferation, metabolism, adhesion, DNA repair, and cell-cycle progression. Although the precise mechanisms by which c-Myc induces oncogenesis remain to be elucidated, c-Myc may contribute to carcinogenesis by altering cellular metabolism, stimulating DNA replication, and/or causing genomic instability. 31, 32 This latter effect may, in part, be due to the 1 ability of c-Myc to induce DNA damage and stimulate chromosomal re-arrangements while inhibiting cell-cycle checkpoint function. [31] [32] [33] [34] Transcription of c-Myc is under the control of multiple, independently acting pathways (reviewed by Wierstra and Alves 35 ). One of these involves the stabilization of the b-catenin transcription factor. 36, 37 Previous reports have suggested that the HCV non-structural protein NS5A is able to activate b-catenin through interactions with the p85 subunit of phosphoinositydol-3 kinase (PI3K) and b-catenin itself. [38] [39] [40] [41] [42] Intriguingly, HCV-associated HCCs demonstrate an elevated presence of activatory mutations in b-catenin.
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The goal of this study was to investigate whether c-Myc expression was altered by HCV infection, and whether any such changes have a role in HCV-induced HCC in vivo. Here, we demonstrate that HCV protein expression in hepatocytes increases c-Myc expression in both infected human livers and livers from FL-N/35 mice expressing the entire HCV ORF; that this overexpression is mediated via the Akt-dependent activation of b-catenin; and that these changes have a crucial role in HCV-associated oxidative stress and genetic damage, likely contributing to HCV-related hepatocarcinogenesis.
RESULTS
c-Myc expression is augmented in non-tumoral liver tissues from HCV-infected patients Since elevated ROS production is frequently observed during chronic HCV infection in humans, and enhanced c-Myc expression has previously been associated with the production of ROS in other cellular contexts, we assessed whether HCV infection was associated with an upregulation of c-Myc. We measured c-Myc expression in liver tissues from cirrhotic and non-cirrhotic HCVinfected patients with or without HCC. In patients with HCC, both tumoral and adjacent non-tumoral liver tissues were studied.
Biopsies from hepatitis B virus (HBV)-infected and -uninfected patients not infected with HCV were used as controls (Table 1) . Quantitative RT-PCR and immunoblotting revealed that c-Myc transcripts (Figures 1a and b) and proteins (Figures 1c and d) were present at significantly higher levels in non-tumoral liver tissues from HCV-infected patients with or without HCC compared with non-tumoral tissues from both uninfected and HBV-infected patients. No difference between cirrhotic and non-cirrhotic individuals was observed (data not shown). These findings demonstrate that HCV infection promotes hepatic c-Myc expression.
c-Myc expression is also augmented in in vitro models of HCV replication We next examined c-Myc expression in hepatoma-derived Huh7 cells harboring replicating subgenomic (genotype 1b) or fulllength (JFH1; genotype 2a) variants of HCV. In both cases, c-Myc transcript levels were significantly higher in the presence of the viral proteins than in uninfected cells (Supplementary Figures S1a  and b ), although the difference was smaller than observed in non-tumoral human liver tissues.
c-Myc expression is elevated in transgenic mice expressing the entire HCV ORF To assess whether the increase in c-Myc expression observed during HCV infection in humans is associated with HCV protein expression alone, we assessed c-Myc expression in the FL-N/35 HCV-transgenic mouse model that expresses the entire HCV ORF. In 15-month-old mice that had not developed HCC, analyses revealed consistently elevated c-Myc transcript and protein levels in the hepatic tissues of FL-N/35 mice compared with wild-type (wt) littermates (Figures 2a and b) . Furthermore, in animals that spontaneously developed HCC (aged between 12 and 24 months), c-Myc expression was significantly higher in the non-tumoral tissues of HCV-transgenic mice compared with wt mice. In contrast, there was no significant difference in c-Myc expression in tumoral tissues from these mice (Figure 2c ). Altogether, our data demonstrate that expression of the HCV proteins alone is associated with the increased c-Myc expression observed in HCV-infected individuals.
Transcription from the c-Myc promoter is stimulated through the stabilization of b-catenin in the presence of HCV proteins To understand the mechanisms elicited by the expression of HCV proteins that lead to enhanced c-Myc expression, we sought to identify the cellular factors responsible. c-Myc is a target of the transcription factor b-catenin. 36 Thus, we examined the nuclear translocation of b-catenin by western blotting analyses of nuclear and total cellular hepatic extracts from FL-N/35 mice and their wt littermates (Figure 3a) , and by indirect immunofluorescence analysis of b-catenin localization in both FL-N/35 and wt primary hepatocytes (Figure 3b ). Both approaches revealed statistically significant increases in the nuclear localization of b-catenin in hepatocytes from HCV-transgenic mice compared with wt controls (Figure 3c) .
To assess the association of b-catenin with the c-Myc promoter, we performed chromatin immunoprecipitation studies in primary hepatocytes from either HCV-transgenic or wt animals. Chromatin Since HCV NS5A has been suggested to activate b-catenin via interaction with PI3K subunit p85, 39, 40 we next examined whether this viral protein was responsible for our observations. Immunoprecipitation experiments confirmed that NS5A immunoprecipitated with PI3K p85 in cells harboring the HCV subgenomic replicon (Supplementary Figure S3a) . Moreover, overexpression of NS5A in wt murine primary hepatocytes increased Akt phosphorylation (Supplementary Figure S3) and stimulated both c-Myc transcription ( Figure 4e ) and protein expression (Supplementary Figure S3b) . In concert, these data pinpoint Akt activation by HCV NS5A as crucial in HCV-mediated c-Myc transcription.
Elevated c-Myc expression participates in the increased ROS production in transgenic mice expressing the entire HCV ORF As previously mentioned, hepatic ROS levels were significantly elevated in fresh liver sections from FL-N/35 mice compared with their wt littermates, using dihydroethidium (DHE) as a marker for intracellular ROS (Figure 5a ). ROS levels were similarly significantly higher in cultured primary hepatocytes isolated from FL-N/35 animals than in those from wt littermates (Figure 5b ). To assess the role of c-Myc in the production of ROS in this context, we transfected primary murine hepatocytes with siRNAs targeting c-Myc. Depletion of c-Myc had a significantly deleterious effect on the production of ROS in FL-N/35 hepatocytes; however, ROS levels were not restored to those observed in cultures from wt animals ( Figure 5c ). In concert, these findings suggest that enhanced c-Myc expression participates in HCV-associated oxidative stress.
c-Myc-related ROS production in the presence of the HCV proteins is due to perturbed cytochrome P2C9 expression Increased ROS production induced by c-Myc has been associated with transcriptional deregulation of several components of the mitochondrial respiratory chain, including cytochrome P2C9 (CYP2C9), a transcriptional target of c-Myc and a component of cytochrome P450 (CYP450). 22, 46 We therefore analyzed both CYP2C9 expression in HCV-infected patients, and expression of the murine equivalent (CYP2C29) in FL-N/35 mice relative to controls. Such analyses revealed that CYP2C9 mRNA expression was significantly higher both in HCV-infected patients compared with non-HCV infected patients, in FL-N/35 mice compared with wt animals (Figures 5d and e) , and in primary hepatocytes isolated from FL-N/35 mice compared with controls (Figure 5f ). Moreover, RNAi-mediated silencing of c-Myc reduced CYP2C29 mRNA levels to wt levels in FL-N/35 primary hepatocytes, demonstrating a direct role of c-Myc in this process (Figure 5f ).
To confirm that CYP2C9 was mechanistically involved in HCVassociated ROS production, we treated primary hepatocytes from either wt or FL-N/35 mice with the CYP2C9 inhibitor sulfaphenazole. Such treatment inhibited ROS production in primary hepatocytes from FL-N/35 mice (Figure 5g ), confirming a contributory role for CYP2C9 in HCV-associated oxidative stress. These data suggest that, in the presence of the HCV proteins, c-Myc has a role in ROS production via upregulation of CYP2C9.
c-Myc-related ROS production in the presence of the HCV proteins is associated with reduced mitochondrial genome integrity Since c-Myc has also been linked to both mitochondrial proliferation and mitochondrial instability, 47, 48 we reasoned that both c-Myc expression and ROS production may promote mitochondrial genomic instability in HCV-infected hepatocytes. Therefore, we examined mitochondrial DNA (mtDNA) integrity in non-tumoral liver tissues from patients with HCCs who were chronically infected with HCV, using a previously described PCR approach. 49 This technique exploits the rationale that genetic lesions randomly distributed throughout the mitochondrial genome are more likely to hamper amplification of a long stretch of mtDNA than a very short fragment. Similar biopsies from HBV-infected and uninfected patients were used as controls ( Table 1) . The results shown in Figure 6a demonstrate that, while amplification of the 311-bp mtDNA fragment was equivalent among all patients, the longer (4566 bp) mtDNA fragment was less efficiently amplified from HCV-infected individuals than from the controls, suggesting that mtDNA integrity was compromised in these patients. Similar analyses revealed increased mitochondrial instability in FL-N/35 mice compared with their wt littermates (Figure 6b ). These data suggest that expression of the HCV proteins is associated with mitochondrial instability.
Increased c-Myc expression is associated with increased DNA damage and defective G1/S arrest in transgenic mice expressing the entire HCV ORF Given that both elevated ROS levels and c-Myc expression are associated with single-stranded DNA (SSD) damage, we examined whether the incidence of SSD damage was elevated in FL-N/35 mice. We therefore assessed the levels of nuclear-localized Apex1, a marker for oxidative SSD damage 22 and a direct c-Myc target, 50 in cultures of primary hepatocytes from FL-N/35 and wt animals. Such analyses revealed significantly higher nuclear Apex1 levels in hepatocytes isolated from HCV-transgenic animals ( Figure 7a ). Moreover, siRNA-mediated knockdown of c-Myc and b-catenin significantly reduced nuclear localization of Apex1, in HCVtransgenic, but not in wt hepatocytes. Nevertheless, these levels remained higher than in controls. These findings demonstrate that HCV-elevated c-Myc expression is associated with increased Apex1 expression, probably in response to elevated oxidative DNA damage (Figure 7b ). c-Myc overexpression has also been linked with defective G1/S cell-cycle arrest after genetic damage. 34 We thus examined the ability of primary hepatocytes from FL-N/35 or wt animals to elicit a G1/S arrest by BrdU incorporation after UV-C treatment 
DISCUSSION
Although cirrhosis appears to be required for HCC development in the vast majority of HCV-infected patients, a direct role for viral proteins in the initiation of liver carcinogenesis is likely. Indeed, an increasing body of literature demonstrates that the HCV viral proteins (particularly core, NS3 and NS5A) perturb host cell cellular pathways involved in hepatocarcinogenesis. 6, 7 A single study has suggested a potential role for HCV core in activating the c-Myc promoter in hepatoma cells. 51 However, to date, no studies have examined the impact of HCV proteins on c-Myc expression in physiologically relevant models, particularly in the context of expression of the entire repertoire of viral proteins. In the present study, we demonstrate for the first time that the HCV proteins induce c-Myc expression in both HCV-infected patients and in mice expressing the entire HCV ORF in a liver-specific manner. Indeed, livers from both models exhibited significantly increased c-Myc mRNA and protein levels in non-tumoral tissues (in both the presence and absence of cirrhosis in the patients). Our observations were confirmed in the context of viral RNA replication in hepatoma cell lines harboring either an HCV genotype 1b subgenomic replicon or the infectious genotype 2a JFH1 strain, although in these instances c-Myc expression was increased to a lesser extent, probably due to the tumoral nature of the cell lines used. Overall, we provide novel evidence that c-Myc expression is specifically induced during HCV infection by the viral proteins. Interestingly, we observed no effect of HBV infection on c-Myc expression, in contrast to reports suggesting that the HBV X protein is capable of inducing c-Myc expression. 52 These discrepancies may reflect the use of hepatoma cell lines and/or the relatively high in vitro expression levels of the HBV X protein in these previous studies.
Previous works have suggested that murine pathways of tumorigenesis closely resemble those found in humans. 53 In agreement, our data from infected patients closely mirrors data from our HCV-transgenic murine model. We thus used the FL-N/35 mouse model for further characterization of the mechanisms involved in HCV-related c-Myc induction and its biological consequences on pathways likely implicated in hepatocarcinogenesis.
Activation of b-catenin was observed in the presence of the HCV proteins in FL-N/35 but not in wt mice. This was due to activation of the upstream PI3K-Akt pathway by the HCV nonstructural proteins. In contrast to Ray et al., 51 our data do not support a prominent role for HCV core in c-Myc promoter activation, although this mechanism may have a minor role in our observations. Furthermore, Akt phosphorylation and c-Myc transcription were induced by HCV NS5A expression in murine hepatocytes, in agreement with previous in vitro studies reporting PI3K/Akt-dependent b-catenin activation in the presence of HCV NS5A. [38] [39] [40] [41] [42] 54 It remains possible that GDF-15 upregulation by HCV also participates in Akt activation. 55 Mechanistically, we showed that the c-Myc promoter is activated by b-catenin in the presence of HCV proteins, with targeted silencing of b-catenin reducing c-Myc promoter activity and transcription in FL-N/35 hepatocytes. These latter findings are in contrast to a study suggesting that c-Myc is not a downstream target of oncogenic b-catenin in a mouse model in vivo, 56 but are in agreement with a more recent study showing such a relationship. 52 It is plausible that either the presence of the HCV proteins (notably NS5A), or the expression of mutated b-catenin in the former model, account for these differences.
Importantly, we show here for the first time that HCV-induced expression of the c-Myc oncogene impacts on ROS production and on the incidence of, and cellular response to, genetic damage. Our finding that elevated hepatic c-Myc expression induced by the expression of HCV proteins contributes directly to ROS production in vivo is in agreement with previous studies showing that c-Myc induces ROS production in various cell types in vitro. [19] [20] [21] [22] [23] [24] [25] It also provides an explanation for the observation that, in similar models or those expressing a single HCV protein, expression of the HCV proteins engenders increased ROS production in vivo. 17, [57] [58] [59] We found that overexpression of cytochrome CYP2C9 induced by c-Myc was a major contributory factor to ROS generation in FL-N/35 mice, in concordance with data obtained in the context of c-Myc overexpression in lymphocytes and fibroblasts in vitro. 22 Nevertheless, neither RNAi silencing of c-Myc expression nor inhibition of CYP2C9 activity restored ROS production to wt levels, in line with the probable role of numerous other pathways in HCV-induced ROS production in vitro and in vivo. Previously, it was demonstrated that c-Myc expression perturbed G1/S checkpoint activity. 34 Consistent with these data, hepatocytes isolated from HCV-transgenic mice exhibited c-Mycdependent defective G1/S cell-cycle arrest after UV-C exposure. In addition, hepatocytes from HCV-transgenic animals exhibited increased progression into S phase, in agreement with previous studies using this model. 10, 11 Taken together, aberrant cell-cycle arrest and genetic damage induced by c-Myc likely contribute to the development of somatic mutations, and therefore may contribute to the onset and progression of HCV-associated HCC. However, since c-Myc has been closely linked with chromosomal instability, it is unclear why HCV-related HCCs exhibit relative chromosomal stability when compared with HCCs of different etiological backgrounds. Our findings suggest that c-Myc induction by HCV proteins has solely an initiatory role in HCVrelated HCC.
In conclusion, our data demonstrate that HCV proteins, notably NS5A, promote hepatic expression of c-Myc through b-catenindependent activation of its promoter, impacting ROS production, DNA repair and cell-cycle regulation. These results strongly suggest that HCV has a direct effect on liver tumorigenesis.
MATERIALS AND METHODS

Human liver tissues
Liver biopsies were from patients infected with HCV or HBV and uninfected patients, in the presence or absence of cirrhosis. Both non-tumoral and tumoral liver tissues from patients with HCC, and liver tissues from patients without HCC, were examined. The patients' characteristics are described in Table 1 .
Cell culture models
The culture of Huh7.5 cells harboring the HCV subgenomic replicon, and of HuaP cells infected with the HCV infectious strain JFH-1, gifts from Dr Ralf Bartenschlager and Dr Czeslaw Wychowski, respectively, has been described previously. ), were bred and maintained as previously detailed.
14 Age-matched 15-month-old male littermates were used for transcriptional and proteomic studies. Primary murine hepatocytes from age-matched 7-to 10-month-old female animals were isolated and cultured as described previously. 12 Spontaneously arising tumors and corresponding non-tumoral tissues from 12-to 24-month old C3H mice (wt and FL-N/35) were used for western blotting.
RNA interference
The siRNAs used in this study were Silencer Select oligos purchased from Applied Biosystems (Foster City, CA, USA). siRNAs were transfected by electroporation using a Nucleofector kit (Lonza, Basel, Switzerland).
Chromatin immunoprecipitation, primers and PCR
Chromatin immunoprecipitation analyses were carried out as described, 60 using freshly isolated murine hepatocytes (5 Â 10 5 cells). After chromatin immunoprecipitation with an anti-b-catenin antibody or an IgG control, the c-Myc or GAPDH promoters were amplified from the resulting DNA by semiquantitative PCR using specific oligonucleotide primers (primers and conditions are detailed in Supplementary Information). Results are presented as percent input by dividing values obtained from total input multiplied by 100. . Plasmids were transfected into primary hepatocytes using Lipofectamine-LTX (Invitrogen, Carlsbad, CA, USA). Luciferase assays were carried out as previously described. 14 
Western blotting and antibodies
Cell fractionation, lysate preparation and western blotting were carried out as described previously.
14 Relative signal intensities were quantified using an Image Quant Las 4000 Mini scanner and Image Quant software (GE Healthcare, Chalfont St. Giles, UK). Primary antibodies were from Cell Signaling (Danvers, MA, USA). Anti-NS5A antibody was a kind gift from Professor Mark Harris (University of Leeds, UK). Rabbit IgG was from SigmaAldrich (St Louis, MO, USA). HRP-conjugated rabbit-anti goat IgG was from GE Healthcare. FITC-conjugated anti-mouse antibody was from Bio-Rad (Hercules, CA, USA), and AlexaFluor 594-conjugated goat anti-rabbit IgG was from Invitrogen.
RNA isolation and quantitative real-time PCR analysis
RNA isolation, analysis and RT-qPCR were carried out in the manner described formerly.
14 All qPCR probes were obtained from Applied Biosystems, and are shown in Supplementary Information.
Immunofluorescence analysis of b-catenin localization Primary murine hepatocytes (5 Â 10 5 cells/chamber) were plated onto Permanox slides (4-well chamber system; Lab-Tek, ThermoFisher Scientific, Fremont, CA, USA). Cells were fixed with methanol and stained for b-catenin expression. Bound antibody was detected using Alexa-594-conjugated anti-rabbit antibody, and images were captured as previously described.
14 The resultant images were quantitatively analyzed using ImageJ software (NIH).
Analysis of Akt kinase activity
Akt kinase activity was analyzed using an Akt Non-Radioactive Kinase Kit (Cell Signaling). Briefly, hepatic biopsies (0.5 mg) or isolated primary cells (5 Â 10 6 cells) were lysed, active Akt was immunoprecipitated and its ability to phosphorylate GSK-3 in vitro was analyzed by western blotting. Relative Akt activities are expressed as the levels of phospho-GSK3 normalized to Akt expression in the unprecipitated input.
Detection of intracellular ROS
Fresh liver sections (10 mm) from wt and FL-N/35 mice were probed for the presence of ROS as described previously. 17 Alternatively, cultures (1 Â 10 5 cells) of unfixed murine hepatocytes grown in collagen-coated glass Labtek chambers (4-well chamber system; ThermoFisher Scientific) were incubated with 5 mM DHE in DMEM for 1 h at 37 1C, and examined by immunofluorescence. In each case, the percentage of ROS-specific cells was calculated, and normalized to wt controls. Where appropriate, cells were treated with 10 mM sulfaphenazole (Sigma-Aldrich) in DMSO for 12 h before ROS detection.
Immunofluorescence analysis of SSD damage Primary murine hepatocytes (5 Â 10 5 cells/chamber) were transfected with siRNAs and plated onto Permanox slides (4-well chamber system). Cells were fixed and stained for Apex1 as previously described. 22 Bound antibody was detected using FITC-conjugated anti-mouse antibody, and images were captured as described previously. The percentage of Apex1-positive nuclei was calculated for each field of view at Â 20 magnification. Data represent the mean±s.e.m. percent of positive cells from at least 300 cells from three independent cultures.
Mitochondrial stability analysis
Total hepatic DNA was isolated from human liver biopsies or murine livers using standard phenol/chloroform procedures. PCR analysis of mtDNA stability was performed as described previously, 49 using the Advantage 2 PCR System (Clontech, Mountain View, CA, USA). The primers and conditions used are detailed in Supplementary Information.
BrdU incorporation assays
Primary murine hepatocytes transfected with siRNAs were plated onto Permanox slides. After 24 h in the presence of EGF (40 ng/ml), cells were treated with 25 J/m 2 UV-C, and 10 mM of BrdU was added. After an additional 24 h, cells were fixed and stained for BrdU, and the percentage of BrdU-positive nuclei was calculated for each field of view at Â 40 magnification. Data represent the mean ± s.e.m. percent of positive cells from at least 300 cells from 3 independent cultures.
Statistical analysis
Results are expressed as mean values±s.e.m. The Mann-Whitney or Wilcoxon non-parametric tests were used, as appropriate.
